Compare GRPN & PRTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GRPN | PRTA |
|---|---|---|
| Founded | 2008 | 2012 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Advertising | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 576.7M | 482.3M |
| IPO Year | 2011 | 2013 |
| Metric | GRPN | PRTA |
|---|---|---|
| Price | $11.98 | $9.79 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 4 | 9 |
| Target Price | ★ $31.25 | $19.00 |
| AVG Volume (30 Days) | ★ 825.7K | 383.0K |
| Earning Date | 01-01-0001 | 05-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 14.69 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $2,843,877,000.00 | $814,000.00 |
| Revenue This Year | $4.17 | $1,111.38 |
| Revenue Next Year | $10.63 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $9.21 | $4.32 |
| 52 Week High | $41.26 | $14.60 |
| Indicator | GRPN | PRTA |
|---|---|---|
| Relative Strength Index (RSI) | 36.85 | 60.48 |
| Support Level | $11.86 | $9.54 |
| Resistance Level | $13.80 | $10.72 |
| Average True Range (ATR) | 0.71 | 0.55 |
| MACD | 0.09 | 0.11 |
| Stochastic Oscillator | 15.21 | 85.94 |
Groupon Inc acts as the middleman between consumers and merchants, offering products and services at discounts via its online store. It offers consumers daily deals from local merchants. The company's operations are organized into two segments: North America and International. The company generates the majority of its revenue from North America. The company generates revenue from transactions during which the company generates commissions by selling goods or services on behalf of third-party merchants. Revenue also includes commissions the company earn when customers make purchases with retailers using digital coupons accessed through its digital properties.
Prothena Corp PLC is a clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including ATTR amyloidosis [Coramitug (PRX004)], Alzheimer's disease (PRX123), Neurodegeneration (PRXPRX019), and Others.